SOD1 and amyotrophic lateral sclerosis: Currently, riluzole, edaravone, AMX0035, and tofersen have been approved by FDA for treating ALS by reducing glutamate release, acting as an antioxidant, mitigating mitochondrial dysfunction, as well as down-regulating superoxide dismutase 1 (SOD1) protein level, respectively.